- Home
- SILO vs TOVX Comparison
SILO vs TOVX Comparison
Compare SILO & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILO
- TOVX
- Stock Information
- Founded
- SILO 2010
- TOVX 2001
- Country
- SILO United States
- TOVX United States
- Employees
- SILO N/A
- TOVX N/A
- Industry
- SILO Apparel
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- SILO Consumer Discretionary
- TOVX Health Care
- Exchange
- SILO Nasdaq
- TOVX Nasdaq
- Market Cap
- SILO 4.5M
- TOVX 4.5M
- IPO Year
- SILO N/A
- TOVX 2006
- Fundamental
- Price
- SILO $0.66
- TOVX $0.42
- Analyst Decision
- SILO
- TOVX Hold
- Analyst Count
- SILO 0
- TOVX 1
- Target Price
- SILO N/A
- TOVX N/A
- AVG Volume (30 Days)
- SILO 537.0K
- TOVX 1.0M
- Earning Date
- SILO 08-13-2025
- TOVX 08-11-2025
- Dividend Yield
- SILO N/A
- TOVX N/A
- EPS Growth
- SILO N/A
- TOVX N/A
- EPS
- SILO N/A
- TOVX N/A
- Revenue
- SILO $72,102.00
- TOVX N/A
- Revenue This Year
- SILO $1.86
- TOVX N/A
- Revenue Next Year
- SILO N/A
- TOVX N/A
- P/E Ratio
- SILO N/A
- TOVX N/A
- Revenue Growth
- SILO N/A
- TOVX N/A
- 52 Week Low
- SILO $0.41
- TOVX $0.37
- 52 Week High
- SILO $3.37
- TOVX $7.15
- Technical
- Relative Strength Index (RSI)
- SILO 49.10
- TOVX 43.60
- Support Level
- SILO $0.56
- TOVX $0.45
- Resistance Level
- SILO $0.73
- TOVX $0.54
- Average True Range (ATR)
- SILO 0.07
- TOVX 0.05
- MACD
- SILO -0.00
- TOVX 0.00
- Stochastic Oscillator
- SILO 43.67
- TOVX 27.94
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.